{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:39:35Z","timestamp":1781883575076,"version":"3.54.5"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":110,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.smim.2020.101427","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T09:19:20Z","timestamp":1605604760000},"page":"101427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era"],"prefix":"10.1016","volume":"50","author":[{"given":"Simone","family":"Pecetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oretta","family":"Finco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2020.101427_bib0005","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jaci.2009.09.017","article-title":"Adaptive immunity","volume":"125","author":"Bonilla","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-018-0278-1","article-title":"An introduction to immunology and immunopathology","volume":"14","author":"Marshall","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0020","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.coph.2018.05.010","article-title":"Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases","volume":"41","author":"Hafeez","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.smim.2020.101427_bib0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev-immunol-042617-053301","article-title":"The antibody response to plasmodium falciparum: cues for vaccine design and the discovery of receptor-based antibodies","volume":"37","author":"Tan","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.chom.2017.07.013","article-title":"Principles of broad and potent antiviral human antibodies: insights for vaccine design","volume":"22","author":"Crowe","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.smim.2020.101427_bib0035","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1084\/jem.20151960","article-title":"Reverse vaccinology 2.0: human immunology instructs vaccine antigen design","volume":"213","author":"Rappuoli","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0040","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrmicro1819","article-title":"The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus","volume":"6","author":"Karlsson Hedestam","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"issue":"1317","key":"10.1016\/j.smim.2020.101427_bib0045","first-page":"1319","article-title":"[The mechanism of diphtheria immunity and tetanus immunity in animals. 1890]","volume":"28","author":"von Behring","year":"1991","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/COH.0000000000000154","article-title":"History of passive antibody administration for prevention and treatment of infectious diseases","volume":"10","author":"Graham","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.smim.2020.101427_bib0055","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrmicro974","article-title":"Passive antibody therapy for infectious diseases","volume":"2","author":"Casadevall","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.smim.2020.101427_bib0060","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2471\/BLT.16.178061","article-title":"Therapeutic antibodies for infectious diseases","volume":"95","author":"Sparrow","year":"2017","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.smim.2020.101427_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.smim.2020.101427_bib0070","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2020.101427_bib0075","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants","volume":"102","author":"The IMpact-RSV Study Group","year":"1998","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"10.1016\/j.smim.2020.101427_bib0080","doi-asserted-by":"crossref","first-page":"A132","DOI":"10.1016\/j.vaccine.2018.11.004","article-title":"Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: a review of the current status of the clinical development pipeline","volume":"37","author":"Sparrow","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2020.101427_bib0085","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0090","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.coi.2019.07.005","article-title":"Human monoclonal antibodies for discovery, therapy, and vaccine acceleration","volume":"59","author":"Andreano","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","article-title":"Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity","volume":"26","author":"Niessl","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cmi.2018.04.024","article-title":"Monoclonal antibodies as anti-infective products: a promising future?","volume":"25","author":"Pelfrene","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.smim.2020.101427_bib0110","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0115","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01714-16","article-title":"Safety, tolerability, and pharmacokinetics of medi8897, the respiratory syncytial virus prefusion f-targeting monoclonal antibody with an extended half-life, in healthy adults","volume":"61","author":"Griffin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.smim.2020.101427_bib0120","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.smim.2020.101427_bib0130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2008.01.003","article-title":"Current and future antiviral therapy of severe seasonal and avian influenza","volume":"78","author":"Beigel","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.smim.2020.101427_bib0135","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.antiviral.2013.03.021","article-title":"Broadly neutralizing antibodies against influenza viruses","volume":"98","author":"Laursen","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.smim.2020.101427_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104562","article-title":"New antibody-based prevention and treatment options for influenza","volume":"170","author":"Sedeyn","year":"2019","journal-title":"Antiviral Res."},{"key":"10.1016\/j.smim.2020.101427_bib0145","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ebiom.2018.12.051","article-title":"Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study","volume":"40","author":"Hershberger","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.smim.2020.101427_bib0150","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2019.04.006","article-title":"Advances in respiratory virus therapeutics - a meeting report from the 6th isirv antiviral group conference","volume":"167","author":"Beigel","year":"2019","journal-title":"Antiviral Res."},{"key":"10.1016\/j.smim.2020.101427_bib0155","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00694-18","article-title":"Evaluation of MEDI8852, an anti-influenza a monoclonal antibody, in treating acute uncomplicated influenza","volume":"62","author":"Ali","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.smim.2020.101427_bib0160","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00352-20","article-title":"A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza a virus infection","volume":"64","author":"Lim","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.smim.2020.101427_bib0165","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nri.2017.148","article-title":"Passive immunotherapy of viral infections:\u2019 super-antibodies\u2019 enter the fray","volume":"18","author":"Walker","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0170","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly neutralizing antibodies to HIV and their role in vaccine design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0175","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.coi.2018.04.025","article-title":"Strategies for a multi-stage neutralizing antibody-based HIV vaccine","volume":"53","author":"Andrabi","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0180","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0185","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1126\/science.aad9195","article-title":"HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen","volume":"351","author":"Jardine","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0190","doi-asserted-by":"crossref","first-page":"10618","DOI":"10.1038\/ncomms10618","article-title":"Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice","volume":"7","author":"McGuire","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2020.101427_bib0195","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.cell.2016.07.029","article-title":"Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires","volume":"166","author":"Tian","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.smim.2020.101427_bib0200","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1084\/jem.20161160","article-title":"Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo","volume":"214","author":"Medina-Ramirez","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0205","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax4380","article-title":"A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses","volume":"366","author":"Steichen","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0210","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay7199","article-title":"Targeted selection of HIV-specific antibody mutations by engineering B cell maturation","volume":"366","author":"Saunders","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0215","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.chom.2019.08.014","article-title":"A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge","volume":"26","author":"Pegu","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.smim.2020.101427_bib0220","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.smim.2020.101427_bib0225","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/22221751.2020.1713707","article-title":"Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities","volume":"9","author":"Liu","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.smim.2020.101427_bib0230","article-title":"Basis and statistical design of the passive HIV-1 antibody mediated prevention (AMP) test-of-Concept efficacy trials","volume":"9","author":"Gilbert","year":"2017","journal-title":"Stat. Commun. Infect. Dis."},{"key":"10.1016\/j.smim.2020.101427_bib0235","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","article-title":"Vaccines and broadly neutralizing antibodies for HIV-1 prevention","volume":"38","author":"Stephenson","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0240","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1056\/NEJMp1802256","article-title":"Monoclonal antibodies for emerging infectious diseases - borrowing from history","volume":"378","author":"Marston","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004717","article-title":"The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases","volume":"11","author":"Casadevall","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.smim.2020.101427_bib0250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.smim.2020.101427_bib0255","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for ebola virus infection","volume":"375","author":"Group","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0260","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S1473-3099(18)30397-9","article-title":"Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study","volume":"18","author":"Sivapalasingam","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.smim.2020.101427_bib0265","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study","volume":"393","author":"Gaudinski","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2020.101427_bib0270","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0275","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003888","article-title":"The structural basis for serotype-specific neutralization of dengue virus by a human antibody","volume":"4","author":"Teoh","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0280","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/emmm.201303404","article-title":"A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface","volume":"6","author":"Fibriansah","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0285","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.aaa8651","article-title":"DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers","volume":"349","author":"Fibriansah","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0290","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cell.2015.06.057","article-title":"Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.smim.2020.101427_bib0295","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8336","article-title":"Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus","volume":"8","author":"Wang","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0300","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJMoa2000226","article-title":"Phase 1 trial of a therapeutic anti-yellow fever virus human antibody","volume":"383","author":"Low","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0305","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41587-020-0512-5","article-title":"Developing therapeutic monoclonal antibodies at pandemic pace","volume":"38","author":"Kelley","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.smim.2020.101427_bib0310","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0315","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2020.101427_bib0320","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S2213-2600(20)30161-2","article-title":"Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations","volume":"8","author":"Phua","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.it.2020.04.008","article-title":"Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses: (trends in immunology 41, 355-359; 2020)","author":"Jiang","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0330","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.smim.2020.101427_bib0335","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2020.101427_bib0340","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/infdis\/jiaa228","article-title":"Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019","volume":"222","author":"Zeng","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2020.101427_bib0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102768","article-title":"Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development","volume":"55","author":"de Alwis","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.smim.2020.101427_bib0350","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41577-020-0365-7","article-title":"Passive antibody therapy in COVID-19","volume":"20","author":"Abraham","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0355","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0360","series-title":"Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art.","author":"Siracusano","year":"2020"},{"key":"10.1016\/j.smim.2020.101427_bib0365","series-title":"Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications","first-page":"2003","author":"Wu","year":"2020"},{"key":"10.1016\/j.smim.2020.101427_bib0370","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2020.101427_bib0375","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","author":"Wu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0380","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0385","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1126\/science.abc7424","article-title":"Broad neutralization of SARS-related viruses by human monoclonal antibodies","volume":"369","author":"Wec","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0390","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.smim.2020.101427_bib0395","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc5881","article-title":"Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody","author":"Lv","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0400","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.smim.2020.101427_bib0405","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0410","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0415","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0420","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1126\/science.368.6491.564","article-title":"The race is on for antibodies that stop the new coronavirus","volume":"368","author":"Cohen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0425","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/d41586-020-02360-y","article-title":"Antibody therapies could be a bridge to a coronavirus vaccine - but will the world benefit?","volume":"584","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.smim.2020.101427_bib0430","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.copbio.2008.10.002","article-title":"Antibodies for the treatment of bacterial infections: current experience and future prospects","volume":"19","author":"Bebbington","year":"2008","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.smim.2020.101427_bib0435","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1056\/NEJMra1600266","article-title":"The Human Intestinal Microbiome in Health and Disease","volume":"375","author":"Lynch","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0440","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.tips.2015.11.008","article-title":"Antibody-based biologics and their promise to combat Staphylococcus aureus infections","volume":"37","author":"Sause","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.smim.2020.101427_bib0445","unstructured":"M. G. Sanchez et al., B14. Late breaking clinical trials. pp. A7358-A7358."},{"key":"10.1016\/j.smim.2020.101427_bib0450","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00350-19","article-title":"Randomized, double-blind, placebo-controlled, single-ascending-dose study of the penetration of a monoclonal antibody combination (asn100) targeting staphylococcus aureus cytotoxins in the lung epithelial lining fluid of healthy volunteers","volume":"63","author":"Magyarics","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.smim.2020.101427_bib0455","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3389\/fimmu.2017.01804","article-title":"New strategies using antibody combinations to increase Cancer treatment effectiveness","volume":"8","author":"Corraliza-Gorjon","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0460","doi-asserted-by":"crossref","first-page":"28059","DOI":"10.18632\/oncotarget.8574","article-title":"Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcgamma receptors","volume":"7","author":"Borlak","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.smim.2020.101427_bib0465","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.smim.2020.101427_bib0470","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1128\/CVI.00371-16","article-title":"Synergistic neutralization of pertussis toxin by a bispecific antibody in vitro and in vivo","volume":"23","author":"Wagner","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0475","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1172\/JCI82314","article-title":"Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells","volume":"125","author":"Sung","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.smim.2020.101427_bib0480","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.omtm.2017.08.006","article-title":"In Situ Liver Expression of HBsAg\/CD3-Bispecific Antibodies for HBV Immunotherapy","volume":"7","author":"Kruse","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.smim.2020.101427_bib0485","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01719-17","article-title":"Targeting human-cytomegalovirus-Infected cells by redirecting t cells using an Anti-CD3\/Anti-Glycoprotein B bispecific antibody","volume":"62","author":"Meng","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.smim.2020.101427_bib0490","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.aag3267","article-title":"A \"Trojan horse\" bispecific-antibody strategy for broad protection against ebolaviruses","volume":"354","author":"Wec","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0495","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009655","article-title":"A multifunctional bispecific antibody protects against Pseudomonas aeruginosa","volume":"6","author":"DiGiandomenico","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0500","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1172\/JCI89652","article-title":"Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature","volume":"127","author":"Thanabalasuriar","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.smim.2020.101427_bib0505","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00528-16","article-title":"Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease","volume":"7","author":"Tkaczyk","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.smim.2020.101427_bib0510","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00629-17","article-title":"Multimechanistic monoclonal antibodies (mabs) targeting staphylococcus aureus alpha-toxin and clumping factor a: activity and efficacy comparisons of a mab combination and an engineered bispecific antibody approach","volume":"61","author":"Tkaczyk","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.smim.2020.101427_bib0515","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.aan8630","article-title":"Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques","volume":"358","author":"Xu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101427_bib0520","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.smim.2020.101427_bib0525","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nature16057","article-title":"Novel antibody-antibiotic conjugate eliminates intracellular S. Aureus","volume":"527","author":"Lehar","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.smim.2020.101427_bib0530","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1182\/blood-2014-07-591412","article-title":"Antigen-armed antibodies targeting B lymphoma cells effectively activate antigen-specific CD4+ T cells","volume":"125","author":"Yu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.smim.2020.101427_bib0535","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1517\/14712598.2016.1161753","article-title":"Antibody-drug conjugates for non-oncological indications","volume":"16","author":"Liu","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.smim.2020.101427_bib0540","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The Therapeutic Potential of Nanobodies","volume":"34","author":"Jovcevska","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.smim.2020.101427_bib0545","article-title":"Toward Next Generation Immunotherapies and Immunoimaging of Cancer","volume":"8","author":"Chanier","year":"2019","journal-title":"Antibodies Basel (Basel)"},{"key":"10.1016\/j.smim.2020.101427_bib0550","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/jth.13716","article-title":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura","volume":"15","author":"Peyvandi","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.smim.2020.101427_bib0555","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/d41573-019-00104-w","article-title":"Nanobody approval gives domain antibodies a boost","volume":"18","author":"Morrison","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.smim.2020.101427_bib0560","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.3389\/fimmu.2020.01531","article-title":"Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2","volume":"11","author":"Konwarh","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0565","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/19420862.2018.1470727","article-title":"Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs","volume":"10","author":"Larios Mora","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.smim.2020.101427_bib0570","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.cell.2020.05.047","article-title":"Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.smim.2020.101427_bib0575","article-title":"Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2","author":"Huo","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.smim.2020.101427_bib0580","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1172\/JCI72676","article-title":"Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity","volume":"124","author":"Bournazos","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.smim.2020.101427_bib0585","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.abb.2012.03.021","article-title":"Isotype and glycoform selection for antibody therapeutics","volume":"526","author":"Jefferis","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.smim.2020.101427_bib0590","doi-asserted-by":"crossref","first-page":"20054","DOI":"10.1073\/pnas.1911842116","article-title":"Differential requirements for FcgammaR engagement by protective antibodies against Ebola virus","volume":"116","author":"Bournazos","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2020.101427_bib0595","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3389\/fimmu.2018.00597","article-title":"Modulation of dengue\/zika virus pathogenicity by antibody-dependent enhancement and strategies to protect against enhancement in zika virus infection","volume":"9","author":"Khandia","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0600","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.antiviral.2015.10.012","article-title":"Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection","volume":"124","author":"Ramadhany","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.smim.2020.101427_bib0605","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/glycob\/cwaa018","article-title":"Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases","volume":"30","author":"Irvine","year":"2020","journal-title":"Glycobiology"},{"key":"10.1016\/j.smim.2020.101427_bib0610","doi-asserted-by":"crossref","first-page":"20690","DOI":"10.1073\/pnas.1108360108","article-title":"Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant","volume":"108","author":"Zeitlin","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2020.101427_bib0615","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1073\/pnas.1702173114","article-title":"Modulating IgG effector function by Fc glycan engineering","volume":"114","author":"Li","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2020.101427_bib0620","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual approaches to modulating antibody effector functions and circulation half-life","volume":"10","author":"Saunders","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0625","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000323","article-title":"Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody","volume":"17","author":"Gulati","year":"2019","journal-title":"PLoS Biol."},{"key":"10.1016\/j.smim.2020.101427_bib0630","first-page":"7","article-title":"Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC","volume":"3","author":"Natsume","year":"2009","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.smim.2020.101427_bib0635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.smim.2020.101427_bib0640","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0645","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, tolerability and pharmacokinetics of medi8897, an extended half-life single-dose respiratory syncytial virus prefusion f-targeting monoclonal antibody administered as a single dose to healthy preterm infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.smim.2020.101427_bib0650","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fimmu.2013.00185","article-title":"Multi-faceted functions of secretory IgA at mucosal surfaces","volume":"4","author":"Corthesy","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0655","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1128\/JVI.00979-13","article-title":"Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs","volume":"87","author":"Seibert","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2020.101427_bib0660","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.4049\/jimmunol.1003189","article-title":"A novel human IgA monoclonal antibody protects against tuberculosis","volume":"186","author":"Balu","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0665","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1038\/s41467-020-18058-8","article-title":"A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction","volume":"11","author":"Ejemel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2020.101427_bib0670","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1158\/0008-5472.CAN-18-1429","article-title":"Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo","volume":"78","author":"Duperret","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2020.101427_bib0675","doi-asserted-by":"crossref","first-page":"13623","DOI":"10.18632\/oncotarget.24426","article-title":"Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies","volume":"9","author":"Hollevoet","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.smim.2020.101427_bib0680","doi-asserted-by":"crossref","first-page":"13","DOI":"10.18632\/oncotarget.26535","article-title":"Simplifying checkpoint inhibitor delivery through in vivo generation of synthetic DNA-encoded monoclonal antibodies (DMAbs)","volume":"10","author":"Perales-Puchalt","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.smim.2020.101427_bib0685","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ymthe.2018.10.016","article-title":"Development of novel DNA-Encoded PCSK9 monoclonal antibodies as lipid-lowering therapeutics","volume":"27","author":"Khoshnejad","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2020.101427_bib0690","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41541-017-0020-x","article-title":"DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections","volume":"2","author":"Elliott","year":"2017","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.smim.2020.101427_bib0695","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/infdis\/jiw111","article-title":"Rapid and long-term immunity elicited by dna-encoded antibody prophylaxis and dna vaccination against chikungunya virus","volume":"214","author":"Muthumani","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2020.101427_bib0700","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","article-title":"How mRNA therapeutics are entering the monoclonal antibody field","volume":"17","author":"Van Hoecke","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0705","doi-asserted-by":"crossref","first-page":"14630","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2020.101427_bib0710","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.15252\/emmm.201707678","article-title":"mRNA mediates passive vaccination against infectious agents, toxins, and tumors","volume":"9","author":"Thran","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.smim.2020.101427_bib0715","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1038\/s41467-018-06508-3","article-title":"Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection","volume":"9","author":"Tiwari","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2020.101427_bib0720","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw6647","article-title":"A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection","volume":"4","author":"Kose","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.smim.2020.101427_bib0725","doi-asserted-by":"crossref","unstructured":"J. Cohen, Designer antibodies could battle COVID-19 before vaccines arrive, https:\/\/www.sciencemag.org\/news\/2020\/08\/designer-antibodies-could-battle-covid-19-vaccines-arrive. doi:10.1126\/science.abe1740.","DOI":"10.1126\/science.abe1740"},{"issue":"2020","key":"10.1016\/j.smim.2020.101427_bib0730","article-title":"Identification of structurally related antibodies in antibody sequence databases using rosetta-derived position-specific scoring","author":"Finn","year":"1993","journal-title":"Structure"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532320300439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532320300439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:22:33Z","timestamp":1760916153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532320300439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":146,"alternative-id":["S1044532320300439"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2020.101427","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2020.101427","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101427"}}